Literature DB >> 14741739

Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK.

S Theoleyre1, Y Wittrant, S Couillaud, P Vusio, M Berreur, C Dunstan, F Blanchard, F Rédini, D Heymann.   

Abstract

Osteoprotegerin (OPG) is a decoy receptor for receptor activator of nuclear factor kappaB ligand (RANKL), an inducer of osteoclastogenesis via its receptor RANK. We recently demonstrated that OPG also exerts a direct effect in osteoclasts by regulating protease expression. Herein, we showed that OPG-induced pro-matrix metalloproteinase-9 activity was abolished by ras/MAPK inhibitors in purified osteoclasts. OPG induced the phosphorylation of p38 and ERK1/2 in RAW264.7 cells. Only p38 activation was totally abolished by a blocking anti-RANKL antibody or an excess of RANKL. Surface plasmon resonance experiments revealed that RANK, RANKL and OPG are able to form a tertiary complex. These results suggested a potential formation of a tertiary complex RANK-RANKL-OPG on osteoclasts. Thus, OPG is not only a soluble decoy receptor for RANKL but must be also considered as a direct effector of osteoclast functions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14741739     DOI: 10.1016/j.bbamcr.2003.10.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Proteoglycans and osteolysis.

Authors:  Marc Baud'Huin; Céline Charrier; Gwenola Bougras; Régis Brion; Frédéric Lezot; Marc Padrines; Dominique Heymann
Journal:  Methods Mol Biol       Date:  2012

2.  Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain.

Authors:  Akinori Kusumi; Hirotaka Sakaki; Tomomi Kusumi; Mitsuo Oda; Kenji Narita; Hiroshi Nakagawa; Kohsei Kubota; Hisashi Satoh; Hiroto Kimura
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

3.  Osteoprotegerin levels in patients with severe mental disorders.

Authors:  Sigrun Hope; Ingrid Melle; Pål Aukrust; Ingrid Agartz; Steinar Lorentzen; Nils Eiel Steen; Srdjan Djurovic; Thor Ueland; Ole A Andreassen
Journal:  J Psychiatry Neurosci       Date:  2010-09       Impact factor: 6.186

4.  Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts.

Authors:  Lele Hou; Jiafa Hou; Jing Yao; Zhenlei Zhou
Journal:  Acta Vet Scand       Date:  2011-03-24       Impact factor: 1.695

Review 5.  Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences.

Authors:  Dominique Heymann
Journal:  J Bone Oncol       Date:  2012-04-26       Impact factor: 4.072

6.  Potential mechanisms of osteoprotegerin-induced damage to osteoclast adhesion structures via P2X7R-mediated MAPK signaling.

Authors:  Yonggang Ma; Xueni Shi; Hongyan Zhao; Ruilong Song; Hui Zou; Jiaqiao Zhu; Zongping Liu
Journal:  Int J Mol Med       Date:  2022-03-10       Impact factor: 4.101

7.  Expression of bone resorption genes in osteoarthritis and in osteoporosis.

Authors:  Darja Bitenc Logar; Radko Komadina; Janez Prezelj; Barbara Ostanek; Zoran Trost; Janja Marc
Journal:  J Bone Miner Metab       Date:  2007-06-25       Impact factor: 2.976

Review 8.  Roles of Mitogen-Activated Protein Kinases in Osteoclast Biology.

Authors:  Kyunghee Lee; Incheol Seo; Mun Hwan Choi; Daewon Jeong
Journal:  Int J Mol Sci       Date:  2018-10-01       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.